MALVERN, Pa.--(BUSINESS WIRE)--Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential ...

Compared with meropenem, cefepime-taniborbactam is superior for microbiologic and clinical cure of complicated urinary tract infection, including acute pyelonephritis. Cefepime-taniborbactam is more ...

Cefepime-taniborbactam, an investigational beta-lactam and beta-lactamase inhibitor combination, was superior to meropenem for the treatment of hospitalized patients with complicated urinary tract ...

Wockhardt files for European marketing approval of WCK 5222, a novel antibiotic targeting multi-drug resistant infections.

The phase 3 CERTAIN-1 study compared the efficacy and safety of cefepime-taniborbactam to meropenem in 661 adults with cUTI. Positive results were announced from a phase 3 study evaluating ...

Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royalties ADVANZ gains commercial rights for cefepime/enmetazobactam in the European Union, the ...

Venatorx Pharmaceuticals and the Global Antibiotic Research and Development Partnership (GARDP) today announced a collaboration to accelerate the development of, and access to, cefepime-taniborbactam ...

Cefepime-taniborbactam was 22% more effective than meropenem, which is a current treatment for complicated urinary tract infections (UTIs) and acute pyelonephritis, according to a study published in ...

Credit: Getty Images. A PDUFA target date of February 22, 2024 has been set for this application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- In ...

The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) will collaborate with the U.S. Department of Defense’s Defense Threat Reduction ...

People believed to have sepsis who take piperacillin-tazobactam (Zosyn) and vancomycin have a 5% absolute mortality increase at 90 days compared with those who take cefepime and vancomycin, a new ...